Kossel

Kossel Medtech (Suzhou) Co., Ltd. was established in November 2013 as a platform enterprise with comprehensive production and R&D capabilities for vascular interventional devices, dedicated to providing systematic solutions for clinical use. The company focuses on the R&D of innovative medical devices in the fields of peripheral intervention, cardiac electrophysiology, and coronary intervention. With systematic independent innovation R&D capabilities and leading production and manufacturing capabilities, Kossel has nearly a hundred intellectual property rights, a 5,000-square-meter R&D and production base, and professional R&D and testing laboratories. Adhering to the quality policy of "customer-centered, developing products of excellent quality," Kossel has successively obtained certifications such as ISO13485, EU CE, US FDA, Japan PMDA, and South Korea KFDA. Kossel has established a wholly-owned subsidiary, Haiyu Xincheng, which focuses on the research of innovative cryoablation technologies, and its core innovative product is about to enter clinical trials. To provide professional CDMO technical services to high-end medical device companies both domestically and internationally, Kossel is planning to establish a new subsidiary, HAITUO Jingchuang. Since its establishment, Kossel has received strong support from governments at all levels, being successively recognized as a leading enterprise at the provincial, municipal, and district levels, undertaking major scientific and technological achievement transformation projects in Jiangsu Province, and successfully being included in the list of Suzhou's "Gazelle" cultivation enterprises and Suzhou's "Unicorn" cultivation enterprises.